FINNENCE ▪ THE WIRE FILE
THE WIRE · № 85434
News■ Unclear/unknown
Vivacta Bio and Grit Bio Announce FDA Orphan Drug Designation for In Vivo CAR-T Therapy GT801 in Autoimmune Hemolytic Anemia
KINDNews
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN
LAST UPDATE
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
Orphan drug designation is a regulatory milestone for a private biotech; no listed ticker is directly affected.
Minor regulatory win for private CAR-T developer
CATALYST TO WATCH
Clinical trial data readouts
MAIN RISK
Early-stage therapy may fail trials
FULL DISPATCH
SHANGHAI, Oct. 17, 2026 /PRNewswire/ -- Vivacta Biotechnology (Shanghai) Co., Ltd. ("Vivacta Bio"), a company spun out of the in vivo CAR-T platform of Beijing Grit Biotherapeutics Co., Ltd. ("Grit Bio"), today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
←CORRELATIONshares Healthcare
Viatris Receives U.S. FDA Approval for RYZUMVI® for the Treatment of Presbyopia2026-10-16 20:05 UTC
Viatris Receives U.S. FDA Approval for RYZUMVI® for the Treatment of Presbyopia2026-10-16 20:05 UTC
←CORRELATIONshares Healthcare
Eli Lilly buys about $12.3M in TRex Bio (TRXB) IPO shares, adding to its holdings.2026-10-16 20:19 UTC
Eli Lilly buys about $12.3M in TRex Bio (TRXB) IPO shares, adding to its holdings.2026-10-16 20:19 UTC
←CORRELATIONshares Healthcare
AMCP Market Insights Findings Show Uncertainty in Biomarker Testing for ESR1-Mutated Advanced Breast Cancer as Payers Weigh Earlier Detection and a Growing Class of Targeted Therapies2026-10-16 21:03 UTC
AMCP Market Insights Findings Show Uncertainty in Biomarker Testing for ESR1-Mutated Advanced Breast Cancer as Payers Weigh Earlier Detection and a Growing Class of Targeted Therapies2026-10-16 21:03 UTC
←CORRELATIONshares Healthcare
City Therapeutics' Upsized $200M IPO Joins Biotech Wave2026-10-16 21:56 UTC
City Therapeutics' Upsized $200M IPO Joins Biotech Wave2026-10-16 21:56 UTC
←CORRELATIONshares Healthcare
Hospital Operator Challenges NC AG's Power Over Merger2026-10-16 23:29 UTC
Hospital Operator Challenges NC AG's Power Over Merger2026-10-16 23:29 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.